PhotoMathias Reding / Unsplash
PhotoKelly Sikkema / Unsplash
Compare peptides honestly.
How popular peptides actually differ: mechanism, strength of evidence, and regulatory status, laid out side by side with no hype.
Popular comparisons
Semaglutide Tirzepatidevs
One hormone pathway versus two
ComparisonTirzepatide Retatrutidevs
Approved dual agonist versus investigational triple agonist
ComparisonSemaglutide Retatrutidevs
Single agonist versus triple agonist
ComparisonSemaglutide Cagrilintidevs
GLP-1 versus amylin, and why they are studied together
ComparisonBPC-157 TB-500vs
The two most-discussed recovery peptides
ComparisonCJC-1295 Ipamorelinvs
Two different ways to raise growth hormone
ComparisonSermorelin Tesamorelinvs
Two GHRH analogs with different track records
ComparisonCJC-1295 Sermorelinvs
Short-acting versus long-acting GHRH analogs
ComparisonSelank Semaxvs
Two Russian-developed nootropic peptides
ComparisonPT-141 Kisspeptinvs
Brain-signaling versus hormone-signaling approaches
ComparisonEpitalon MOTS-cvs
Two longevity peptides, both early-stage
ComparisonGHK-Cu BPC-157vs
Skin-and-repair peptides with different evidence
How we compare
Mechanism
What each compound actually does in the body, and whether they work through the same pathway.
Evidence
An FDA-approved medicine and an animal-study compound are not equals. We say which is which.
Status
Approved, investigational, or unapproved, stated plainly for all 19 compounds we track.